Perampanel
Epilepsy
In DevelopmentActive
Key Facts
About Ark Diagnostics
Ark Diagnostics is a commercial-stage diagnostics company with a core focus on homogeneous enzyme immunoassay technology for clinical chemistry analyzers. The company has established a diversified portfolio of ready-to-use liquid assays, primarily serving hospital and reference laboratories for therapeutic drug monitoring and forensic/clinical urine drug testing. Its strategy involves continuous assay development, with recent launches in ethyl glucuronide, ketamine, and methotrexate testing, and a pipeline expanding into areas like veterinary diagnostics and oral anticoagulants. Ark operates globally through a distributor network and maintains a presence at key scientific conferences.
View full company profileTherapeutic Areas
Other Epilepsy Drugs
| Drug | Company | Phase |
|---|---|---|
| ADX71149 (mGlu2 PAM) | Addex Therapeutics | Phase 2 |
| TRV045 | Trevena | Phase 1 |
| SAGE-324 | Sage Therapeutics | Preclinical |
| Motpoly XR™ | Aucta Pharmaceuticals | Not Specified (Likely Phase 3/NDA) |
| ADB-104 | Adolore BioTherapeutics | Pre-clinical |
| Not Publicly Disclosed | Cerecin | Phase 2 |
| eTNS Platform | NeuroSigma | Unknown |
| NPT 2042 | NeuroPro Therapeutics | Phase 2 |
| Spritam (levetiracetam) | Aprecia Pharmaceuticals | Approved |
| NeuroAccess Platform | Cordance Medical | Pre-clinical/Research |
| Epilepsy Program | Current Surgical | Research |
| GABA-A PAM for Epilepsy | Modulate Bio | Preclinical |